Details

Autor(en) / Beteiligte

• Buchynskyi, Mykhailo
• Kamyshna, Iryna
• Lyubomirskaya, Katerina
• Moshynets, Olena
• Kobyliak, Nazarii
• Oksenych, Valentyn
• Kamyshnyi, Aleksandr

Titel

Efficacy of interferon alpha for the treatment of hospitalized patients with COVID-19: A meta-analysis

Ist Teil von

• Frontiers in immunology, 2023-01, Vol.14, p.1069894-1069894

Ort / Verlag

Switzerland: Frontiers Media S.A

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• IFN-α intervention may block SARS-CoV-2 replication and normalize the deregulated innate immunity of COVID-19. This meta-analysis aimed to investigate the efficacy of interferon IFN-α-containing regimens when treating patients with moderate-to-severe COVID-19. PubMed, SCOPUS, and ClinicalTrials.gov were searched from inception to 15 January 2022. A systematic literature search was conducted by applying relevant terms for 'COVID-19' and 'interferon-α'. The primary outcome enclosed the all-cause hospital mortality. The secondary outcomes constituted the length of hospital stay; hospital discharge; nucleic acid negative conversion. Eleven studies are enclosed in the meta-analysis. No significant difference in the all-cause mortality rate was found between the study and control groups (OR 0.2; 95% CI 0.05-1.2; I = 96%). The implementation of interferon did not influence such outcomes as the length of hospital stay (OR 0.9; 95% CІ, 0.3-2.6; I 91%), nucleic acid negative conversion (OR 0.8; 95% CI, 0.04-17.2; I 94%). Nevertheless, IFN-α treatment resulted in a higher number of patients discharged from the hospital (OR 26.6; 95% CІ, 2.7-254.3; I = 95%). Thus, IFN-α does not benefit the survival of hospitalized COVID-19 patients but may increase the number of patients discharged from the hospital. www.crd.york.ac.uk/prospero, identifier (CRD42022374589).